Lu Wang
Impact in
- Pulmonary and Respiratory Medicine top 0.2%
- Lung Cancer Treatments and Mutations
- Sarcoma Diagnosis and Treatment
- Renal cell carcinoma treatment
- Occupational and environmental lung diseases
- Cancer Research top 1%
- Cancer Genomics and Diagnostics
Papers in
-
- Lung Cancer Treatments and Mutations 24
- Sarcoma Diagnosis and Treatment 23
- Renal cell carcinoma treatment 17
- Hematology 42
- Acute Myeloid Leukemia Research 19
- Hematopoietic Stem Cell Transplantation 16
- Co-authors
- Marc Ladanyi (23 shared papers)Mark G. Kris (9 shared papers)Alexander Drilon (6 shared papers)Maureen Frances Zakowski (5 shared papers)Meera Hameed (18 shared papers)Maria Arcila (10 shared papers)Naiyer A. Rizvi (3 shared papers)Michelle S. Ginsberg (2 shared papers)
- Journals
- Modern Pathology (11 papers)Clinical Cancer Research (10 papers)PLoS ONE (9 papers)Nature Communications (8 papers)Oncotarget (8 papers)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Lu Wang
501 papers receiving 17.7k citations
Lu Wang's Hit Papers
Peers
Comparison fields: 5 of 176
- Pulmonary and Respiratory Medicine 5.7k
- Cancer Research 1.3k
- Oncology 1.7k
- Rheumatology 910
- Molecular Biology 3.6k
Countries citing papers authored by Lu Wang
This map shows the geographic impact of Lu Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lu Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lu Wang more than expected).
Fields of papers citing papers by Lu Wang
This network shows the impact of papers produced by Lu Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lu Wang. The network helps show where Lu Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Lu Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 527 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib Hit paper breakdown → | 2007 | 1431 |
| 2 | The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma Hit paper breakdown → | 2011 | 583 |
| 3 | Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling Hit paper breakdown → | 2011 | 450 |
| 4 | Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas Hit paper breakdown → | 2013 | 403 |
| 5 | Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1 Hit paper breakdown → | 2012 | 402 |
| 6 | Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial Hit paper breakdown → | 2016 | 386 |
| 7 | Population‐Based Incidence and Prevalence of Systemic Lupus Erythematosus: The Michigan Lupus Epidemiology and Surveillance Program Hit paper breakdown → | 2013 | 356 |
| 8 | 2011 | 251 | |
| 9 | 2013 | 247 | |
| 10 | 2014 | 246 | |
| 11 | 2015 | 244 | |
| 12 | 2013 | 232 | |
| 13 | 2015 | 197 | |
| 14 | 2014 | 194 | |
| 15 | 2014 | 181 | |
| 16 | 2016 | 171 | |
| 17 | 2012 | 155 | |
| 18 | 2016 | 155 | |
| 19 | 2015 | 149 | |
| 20 | 2022 | 144 |
About Lu Wang
Lu Wang is a scholar working on Pulmonary and Respiratory Medicine, Hematology, Oncology, Molecular Biology and Cancer Research, having authored 527 papers that have together received 18.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (24 papers), Sarcoma Diagnosis and Treatment (23 papers), Acute Myeloid Leukemia Research (19 papers), Renal cell carcinoma treatment (17 papers), Hematopoietic Stem Cell Transplantation (16 papers), Cancer Genomics and Diagnostics (13 papers), HIV/AIDS Research and Interventions (11 papers) and Genomics and Chromatin Dynamics (10 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (5.7k citations), Cancer Research (1.3k citations), Oncology (1.7k citations), Rheumatology (910 citations) and Molecular Biology (3.6k citations). Lu Wang has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Marc Ladanyi, Mark G. Kris, Alexander Drilon, Maureen Frances Zakowski, Meera Hameed, Maria Arcila, Naiyer A. Rizvi, Michelle S. Ginsberg, Natasha Rekhtman and Jeffrey S. Ross. Their work appears in journals such as Modern Pathology, Clinical Cancer Research, PLoS ONE, Nature Communications and Oncotarget.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.